Dual-variable domain immunoglobulin (DVD-Ig)
Created by Chengbin Wu and Tariq Ghayur
Biologics, Abbott Laboratories (Abbott Park, IL)
(COURTESY OF MERCK RESEARCH LABORATORIES)
|
Targeting a single-disease mediator with a traditional monoclonal antibody (mAb) can result in limited efficacy or partial
response. Preclinical studies in disease models demonstrated that targeting two or more disease mechanisms is far more effective
than targeting a single mechanism, potentially due to the additive or synergistic effect of the dual-targeting strategy. Combining
large molecules in the past has been a significant challenge because multi-specificity-based mAbs had poor pharmacokinetics,
stability, and manufacturing feasibility. The dual-variable domain immunoglobulin (DVD-Ig) platform, discovered by Abbott
scientists, is the first technology to successfully combine the function and specificity of two or more mAbs into one molecule,
thereby creating a combination therapy in a single drug. The DVD-Ig approach has distinct technological and scientific advantages
compared to mAbs. The technology enables the development of new generation biologics that target multiple disease mediators
simultaneously, while displaying excellent drug-like properties and manufacturing efficiency. The approach allows for the
creation of new, improved biologic medicines for complex diseases such as cancer and autoimmune diseases.
|
